Protext Mobility EPS
Earnings per Share (EPS) of Protext Mobility (TXTM) as of Oct 26, 2026.
Get this data via API
Financial Data API
EPS
0.00USD
YoY
-1,304.05%
Last updated:
Earnings per Share (EPS) of Protext Mobility is 2025 0.00 USD. Earnings per Share (EPS) of Protext Mobility was 2024 -0.00 USD. It decreases by -1,304.05% higher compared to the previous year.
The Protext Mobility EPS history
3 Years
10 Years
25 Years
Max
EPS
Date
EPS
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
-0.00 USD
Jan 1, 2024
-0.00 USD
Jan 1, 2025
0.00 USD
| YEAR | EPS | YoY |
|---|---|---|
| 0.00USD | -1,304.05% | |
| -0.00USD | -21.91% | |
| -0.00USD | -109.84% | |
| 0.00USD | -445.22% | |
| -0.00USD | -68.44% | |
| -0.00USD | -66.34% | |
| -0.00USD | -10.23% | |
| -0.00USD | -37.63% | |
| -0.00USD | +824.74% | |
| -0.00USD | +17.14% | |
| -0.00USD | -100.00% | |
| -2.34USD | -73.64% | |
| -8.86USD | -59.23% | |
| -21.74USD | -74.47% | |
| -85.14USD | +74.43% | |
| -48.81USD | -22.41% | |
| -62.91USD | -69.47% | |
| -206.07USD | +147.17% | |
| -83.37USD | -9.58% | |
| -92.20USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Protext Mobility Stock analysis
What does Protext Mobility do? ProText Mobility, Inc. develops pharmaceutical applications for botanical drugs using proprietary live plant extraction technology. The company focuses on research, testing, and development of highly bioavailable botanical products with all-natural ingredients for nutraceutical and pharmaceutical applications. Its subsidiaries include Plandai Biotechnology South Africa (Pty) Ltd. and Cannabis Biosciences, Inc., which support its product development and market reach.
The company generates revenue through the sale of pharmaceutical applications and botanical products developed via its proprietary technology. These products target nutraceutical and pharmaceutical markets, with subsidiaries operating in South Africa and cannabis-related research. The primary buyers are companies in the nutraceutical and pharmaceutical sectors seeking natural, highly bioavailable formulations.
Plandai Biotechnology South Africa (Pty) Ltd. and Cannabis Biosciences, Inc. contribute to the company's revenue streams by expanding its product portfolio and market presence. The firm's focus on all-natural ingredients and proprietary extraction methods differentiates its offerings in the nutraceutical and pharmaceutical industries. Protext Mobility is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Protext Mobility stock
On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Protext Mobility since 2006 – with annual values, charts, and detailed analysis.
Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.
EPS = Net Income / Shares Outstanding
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Protext Mobility
All Key Metrics — Protext Mobility
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth